Therapeutic evaluation of a topical unani formulation in the treatment of Hazaz (Pityriasis capitis): A randomizes open label pilot controlled trial.

Huzaz (pityriasis capitis) also known as dandruff is a prevalant scalp disorder affecting more than half of world adult population. it is considered the  mildest from of seborreic dermatitis involving subclinicaal inflammation. in comparison seborreic dermatitis exihibits a more inflammatroy nature on the scalp. Pityriasis capitis is characterized by increased scalp epidermal proliferation, along with itching and redness. It shows varying levels of severity and is more common in men than women. The condition is most frequently observed in adolescents aged 15-24 years and in older adults above 50 years[4]. The causative organism of pityriasis capitis is Malassezia globosa, a yeast-like fungus that feeds on scalp, feeding on skin oils. Treatment option for dandruff icluding ointment lotions and shampoo. such as zinc pyrithione, salicylic acid, imidazole derivatives, selenium sulfide, tar derivatives, and ketoconazole. However, these synthetic agents are reported to cause side effects like hair loss, increased scaling, itching, nausea, headache, vomiting, photosensitivity, and even cancer. this highlight the need for expooring alternative treatment modakities, where uanani medicine could play a crucial role in providing aq safe and effective treatment. considering all the factors the present study has been desingned to assess the safty and efficacay of a topical unani formulation cosisting of ab-i chuqandar mixed bura armani in managing hazaz comared to ketoconazole 2%.